Pathway to Prevention of Nosocomial Clostridium difficile Infection

Clin Infect Dis. 2015 May 15:60 Suppl 2:S148-58. doi: 10.1093/cid/civ142.

Abstract

Background: To address the significant morbidity and mortality rates associated with nosocomial Clostridium difficile-associated diarrhea (CDAD), a series of recommendations and a pathway to prevention were developed.

Methods: An expert panel of infectious disease (ID) specialists participated in a modified Delphi process with specific objectives: (1) conduct a review for CDAD and prevention; (2) develop statements based upon panel members' opinions; (3) hold a panel meeting during the 2012 IDWeek; and (4) review the final recommendations and prevention pathway prior to submission for publication.

Results: The panel voted on (1) antibiotic stewardship (7 of 8 panelists); (2) reduction of other potentially modifiable risk factors (variable); (3) utilization of specific probiotics to prevent C. difficile overgrowth (8/8); (4) staff education regarding CDAD preventive measures (8/8); (5) appropriate hand hygiene for everyone (7/8); (6) environmental cleaning (8/8); (7) medical equipment disinfection (7/8); (8) early detection of CDAD in symptomatic patients (7/8); (9) usage of protective clothing/gloves (8/8); (10) proper measures during outbreak (8/8); and (11) surveillance to monitor efficacy data of preventive measures (8/8).

Conclusions: The panel members agreed with 11 of 17 recommendations presented. The additional recommendations by the panel were proton pump inhibitor use as a risk factor and the use of adjunctive therapy with specific probiotic, as it was approved by Health Canada for the risk reduction of CDAD in hospitalized patients.

Keywords: CDI; Clostridium difficile; prevention; probiotic.

MeSH terms

  • Canada / epidemiology
  • Clostridioides difficile*
  • Clostridium Infections / prevention & control*
  • Cross Infection / prevention & control*
  • Delphi Technique
  • Disinfection
  • Hand Hygiene
  • Hospitalization
  • Humans
  • Probiotics / therapeutic use*
  • Proton Pump Inhibitors / adverse effects
  • Risk Factors

Substances

  • Proton Pump Inhibitors